Articles tagged "Kidney transplantation"

2017 American Transplant Congress
Microarray Analysis of Rejection in Formalin-Fixed Paraffin-Embedded Biopsies: Similarities and Disparities with Conventionally Stabilized Biopsies.
K. Famulski, J. Revee, P. Halloran.
Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada
Despite potential for performing molecular diagnostics on formalin-fixed paraffin embedded (FFPE) biopsies, there has been no systematic comparison of microarray gene expression data obtained from…
2017 American Transplant Congress
Outcome of Living-Donor Kidney Transplantation in Cross-Match-Positive Recipients at a Single Center.
D. Okada,¹ M. Okumi,¹ K. Unagami,² T. Shimizu,¹ H. Ishida,¹ K. Tanabe.¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Nephrology, Tokyo Women's Medical University, Tokyo, Japan
BackgroundLiving-donor kidney transplantation in cross-match (XM)-positive patients remains high-risk and requires an optimal desensitization protocol. We started a desensitization protocol for XM-positive patients in January…
2017 American Transplant Congress
Impact of a Novel Prehabilitation Program in Kidney Transplant Candidates.
M. McAdams DeMarco, H. Ying, A. Nastasi, D. Segev.
Johns Hopkins, Baltimore, MD
Background: Prehabilitation is the process of enhancing surgical patient functional capacity prior to surgery to improve tolerance for the upcoming physiologic stress. While prehabilitation has…
2017 American Transplant Congress
Kidney-Specific Immunosuppression without Adverse Systemic Effects.
D. Kentrup,¹ K. Schuette-Nuetgen,¹ H. Pawelski,¹ H. Pavenstädt,¹ S. Hermann,² M. Schaefers,² G. Larbig,³ A. Kuebelbeck,³ S. Reuter.¹
¹Department of Medicine D, University Hospital Muenster, Muenster, Germany; ²European Institute for Molecular Imaging - EIMI, University Hospital Muenster, Muenster, Germany; ³Merck KGaA, Darmstadt, Germany
Purpose: Immunosuppressive therapy is often accompanied by severe adverse effects. To overcome this, the aim of this study was the evaluation of a kidney-specific drug…
2017 American Transplant Congress
Solid Organ Cancer After Kidney Transplantation: Risk Factors and Long Term Impact.
A. Buxeda, D. Redondo, M. Pérez-Sáez, A. Bartolomé, M. Mir, A. Pascual, A. Sans, M. Crespo, J. Pascual.
Nephrology Department, Hospital del Mar, Barcelona, Spain
Cancer after kidney transplant (KT) is the only cause of death that is increasing. We analyzed incidence, risk factors and characteristics of postKT solid cancers…
2017 American Transplant Congress
The Incidence, Mortality and Prediction Model for Fractures After Kidney Transplantation in the United States.
X. Liu, S. Bae, M. McAdams DeMarco, D. Segev.
JHU, Baltimore, MD
Kidney transplant (KT) recipients are more likely than general population to have fractures. In the general population, fractures are associated with morbidity, mortality, and high…
2017 American Transplant Congress
Predicting Residual Renal Compensation in Living Kidney Donors Post-Donation.
A. Diez, G. Diltz, J. Von Visger, U. Nori, T. Pesavento, R. Pelletier.
Ohio State University College of Medicine, Columbus, OH
In living kidney donors it is well established that post-donation the remaining kidney undergoes functional hypertrophy; resulting in a 20% – 40% in increase in…
2017 American Transplant Congress
Single-Center Initial Experience in Treating Chronic Hepatitis C in Kidney Transplant Recipients.
G. Meinerz, C. da Silva, R. Bruno, E. Keitel, V. Garcia.
Nephrology and Kidney Transplant Department, ISCMPA, Porto Alegre, RS, Brazil
Chronic hepatitis C (HCV) infection is a prevalent condition in end-stage renal disease and presents an important clinical challenge in kidney transplant recipients (KTR). Interferon-based…
2017 American Transplant Congress
Kidney Recipients with 10 Year Belatacept-Treatment Display an Altered T Cell Subset Composition and Low Plasma Cytokine Levels Compared to Matched Patients with CNI-Based Immunosuppression.
C. Falk,¹ C. Neudörfl,¹ A. Scherf,¹ K. Daemen,¹ J. Keil,¹ J. Klempnauer,² F. Lehner,² G. Grannas.²
¹Institute of Transplant Immunology, IFB-Tx, MHH, Hannover, Germany; ²Department of Abdominal, Visceral and Transplantation Surgery, MHH, Hannover, Germany
Introduction/BackgroundMore than 10 years ago, Belatacept (Bela)-based immunosuppression was investigated in the BENEFIT trial of kidney transplantation (KTx) compared to CNI-based immunosuppression. Bela inhibits T…
2017 American Transplant Congress
Characterization of De Novo Donor-Specific HLA Antibodies and Correlations with C4d+ Antibody-Mediated Rejection of Kidney Transplants.
R. Rajalingam,¹ D. Kopchaliiska,¹ O. Buenaventura,¹ M. Singh,² S. Tomlanovich.²
¹Immunogenetics and Transplantation Laboratory, Depart. of Surgery, University of California San Francisco, San Francisco, CA; ²Transplant Service, Department of Medicine, University of California San Francisc, San Francisco, CA
Aim: Characteristics of de novo donor-specific HLA antibodies (dnDSA) that are associated with C4d positive antibody-mediated rejection (C4d+ AMR) in kidney transplants have not been…